Viral Genetics, Inc., (Pinksheets: VRAL – News) has appointed biofuel specialist John Sheehan to the advisory board. Sheehan will provide leadership as the company develops alliances in the energy industry to accelerate the process of moving their biofuel technology forward.

According to Sheehan, “Viral Genetics is in the right place at the right time with this technology. Identifying and controlling the trigger for lipid production in algae has long been the holy grail of algal biofuels technology. Many big players are working in this field, and whoever is first to translate such a discovery into an economic process will leap frog to the front of the pack” said Sheehan.

http://finance.yahoo.com/news/Viral-Genetics-Appoints-bw-2527337445.html?x=0&.v=1

Disclaimer  :  http://21webir.com/stocks-and-sectors/disclaimer-for-viral-genetics-vral-pink-sheet/

Profile Report July 6, 2010

21^st Century Investor Relations, Inc, is an Investor Relations 2.0  firm that helps small and micro cap companies build investor audiences through the use of Internet marketing and Social Media(“Investor Relations 2.0” or “IR 2.0”). We are looking for undiscovered companies with explosive growth potential within industries of interest, Internet and IT, Energy & Cleantech, and Health Care.  Unlike the vast majority of online stock promotion services we are extremely selective of the client companies we represent. Once prospective companies pass our proprietary selection criteria, we create targeted investor traffic and build audiences online through our Internet marketing efforts

We have been retained by a third party to provide services to Viral Genetics, Inc (VRAL: Pink Sheets). Please read our disclosure carefully and perform due diligence before you invest (see link below):

Viral Genetics (VG) (Pink Sheets: VRAL), headquartered in San Marino, CA is a biotechnology company that develops novel protein-based targeted peptide drugs to treat drug resistant cancers, infectious autoimmune diseases such as Lyme disease, HIV/AIDS, and other medical conditions.

Recent Updates

Viral Genetics accelerates their targeted peptide drug development pipeline through strategic and tactical early stage drug discovery agreements with academic institutions

VG’s combined agreement with scientific researchers at the University of Colorado, Colorado Springs (UCCS) and Texas A & M Health Sciences Center (HSC) College of Medicine, serves to outsource early research and development services and expand VG’s intellectual property portfolio without expending capital.

Viral Genetics has entered into its second collaborative research and development agreement with the Department of Cellular and Molecular Medicine at St George’s, University of London.

The University of London development work will spearheaded by renowned researcher Robin Shattock, Professor of Cellular and Molecular Infection who will be leading a dedicated team of scientists who will be incorporating the Viral Genetics, Inc. lead HIV/AIDS drug compound VGV-X into their well funded R & D programs focused on early stage development of safe and efficacious HIV preventative OTC microbicidal preparations.

Both strategic agreements catapult critical biomedical research and development activities of Viral’s patented targeted peptide technology eliminating millions of dollars of future capital expenditure. While more universities are seeking ways to create new revenue streams, academic research institutions are expanding their discovery work by entering into early stage drug development ventures with private industry companies that are willing to oversee and fund academic teams. Viral Genetics agreements with University of London, Colorado, and Texas A & M, are unique in that it’s virtually unheard of for a university to partner, invest, provide funding, and perform early stage drug development work for private industry early stage drug  product candidates.

During the past 18 months large global pharmaceutical companies have laid off thousands of employees, shut down facilities, and scrapped early stage drug development candidates in order to posture their drug development pipelines as having magically attained a perpetual state of sustained momentum, and as a means to appear profitable.   Large pharma has begun systematically repopulating their scrapped therapeutic portfolios by partnering, licensing or acquiring commercially viable product candidates from early stage companies like Viral whose drug product candidates are successfully positioned to weather safety, tolerability, toxicology and efficacy in animal models.

Through these collaborative agreements with academia, Viral’s executive leadership is capitalizing on the fact that large pharma has placed the onus of early drug discovery on emerging biotech and pharma, and will be well positioned to negotiate licensing deals and/or as an M & A target for large Pharma’s repopulating  and repositioning themselves with successful drug pipelines.

Why we believe Viral’s technology could potentially be transformational

Targeted peptide technologies are among the highest researched within drug discovery since they interrupt and modulate the cell signaling pathway which halts pathogenic processes.   This technology is exploding as potential effective therapy for neoplasm’s, and infectious disease states eliminating the need to use current approved therapies that contribute to resistance which represents a radical paradigm shift from current available therapies used to treat infections to activating the body’s own immune system to attack and destroy infectious pathogens.

Viral Genetics, whose novel protein-based targeted peptide therapeutic candidates have proven to be scientifically validated to effectively disrupt the metabolic pathway halting pathogenesis of neoplasm’s, immune disorders, viruses and/or bacteria from replicating and remaining viable.  Metabolic interruption of disease pathogens could potentially transcend resistance barriers associated with the current approved infectious disease, cancer, and immune disorder therapies.  The regulatory pathway for Viral’s therapeutic pipeline includes compassionate use, OTC, and orphan fast track status IND’s and NDA’s.

Targeted peptide metabolic pathway disruption positions Viral Genetics as a potentially powerful therapeutic, and preventative agent for a myriad of infectious viral and bacterial indications, and is particularly compelling due to the high incidence of transmission and resistance to non-nucleoside /nucleoside reverse transcriptase inhibitors, and protease inhibitors in HIV /AIDS populations. It is anticipated that the work from this strategic alliance will result in potential new therapies and vaccines to protect against the HIV pandemic.

Bio-Informatics & Computational Modeling leveraged to accelerate drug discovery and development. By utilizing computational modeling Viral Genetics’ lead scientist Dr. M. Karen Newell, Ph.D. accelerated the discovery of the mechanisms of action and was able to further define just how Viral Genetics targeted peptide technology navigates through cellular signaling pathways.  Subsequently by mapping their technology to pathogenic neoplasm’s, immune disorders, bacteria and viruses, Dr. Newell confirmed that their technology effectively disrupts the metabolic pathway halting pathogenesis of neoplasm’s, immune disorders, viruses and/or bacteria from replicating and sustaining viability.  Her findings supported the hypothesis that reduction in viral loads were indeed impacted through metabolic disruption which substantiated the clinical trial data where AIDS affected subjects while receiving Viral Genetics VGV-X   experienced a reduction and sustained reduced vial loads.

What a difference a year and a half makes

At the beginning of 2009 Viral Genetics stood on the brink of bankruptcy, unable to pay back a toxic convertible loan of $4,000,000 with the stock trading at $.015.

In June 2009 the Company appeared on the initial pilot episode of the Wide World of Stocks television show, a national syndicated cable show on micro-cap companies with explosive potential growth, and accessible to over 95 million homes nationwide.

In the six weeks following the appearance, the stock exploded running to $.13 up almost 550%, on massive volume of 200 million shares, the equivalent of one result of this tremendous market action approximately $21,000,000 in dollar volume traded in six weeks, the Company was able to retire its toxic convertible loan.

Major turning point as a result of Conversion of debt

The Company is now focused on completing the necessary work to substantiate future IND filings with a solid plan of action and timeline to enter into the proof of principle clinical trial phase to support NDA filings.  As a result of eliminating the debt overhang they are now in a position to raise fresh capital enabling the majority of any new funding to go directly toward drug development.rather than spending all their resources paying back toxic debt.  Viral has expanded its clinical development team to increase the bandwidth with which the company can develop new products to meet critical global market needs.

Why Viral common stock represents a ground floor opportunity with huge potential

Compelling technology and IP as evidence by this tiny Company’s ability to attract some of the world’s most successful scientist and businessmen to its advisory board, several Nobel laureates including Luc Montgainer, who discovered the HIV in 1983, and Marshall Phelps the former head of global IP Policy strategy for Microsoft .

Highly competent management and strategy driven scientific team who take very seriously their responsibility to develop preventative and therapeutic drugs that transcend current resistance barriers, and will not contribute to new resistance or virulence.

Viral is transitioning from early stage discovery and entering into the R&D phase needed to support the regulatory pathways of IND and NDA filings. We could potentially start getting IND announcements beginning in the current Quarter.  As the Company reports substantive news on completion of toxicology, non-clinical and animal studies  the stock could make a massive move.

A number of Wall Street analyst are calling for a bubble in the next few years in early stage biotech stock sector, as a result of the above trend of large Pharma outsourcing to emerging biotech companies. As significant discoveries turn some biotech stocks into lottery tickets.  A lot of people will be trying to catch lightning in a bottle and looking for potential 100 to1 payoffs for small companies like Viral.

Unconventional financing sources represent a means of advancing Viral’s technology while reducing the need to dilute shareholders by issuing stock. Due to the importance of Viral Genetics drug development candidates transcending resistance barriers the company intends to continue to explore and tap into unconventional funding sources not available to companies whose drug development pipelines contain therapeutic agents that inevitability will contribute to resistance.

VRAL is not a widows and orphans stock. An investment in Viral Genetics, Inc (VRAL: Pink Sheets) is suitable for speculative investors only.  If you can’t afford to lose all your money don’t get involved with Viral. But for those with a strong risk tolerance and looking to build a position in this name this could be a $.20 by year end and as specific milestones along the road to commercialization with the ultimate goal of hitting the jackpot and having one of technologies licensed by a major Pharmaceutical company the stock has the potential to explode by 10-50 folds from current levels.

Please read our disclosure carefully and do due diligence before you invest (see link below):http://21webir.com/stocks-and-sectors/disclaimer-for-viral-genetics-vral-pink-sheets/

We have a follow up piece of our initial April 12, 2010 profile report coming out in the next few days.

VRAL trading at its support level is an ideal accumulation point for those looking to build a position in this speculative company with a potential to be a 10-50 fold winner over the next 18-36 months, as the drug therapies under development possibly reach specific milestones.

For traders VRAL has popped 20% multiple times from its current support level including just last Monday

http://21webir.com/stocks-and-sectors/disclaimer-for-viral-genetics-vral-pink-sheets/

The news from Monday was probably the most significant piece of news in the 10 year plus history of Viral Genetics Inc. (VRAL: PINK SHEETS)

http://finance.yahoo.com/news/Viral-Genetics-HIVAIDS-bw-1583274227.html?x=0&.v=1

The question is how much money would it cost to conduct research and possible trials on Viral’s Targeted Peptide Technology (TPT) to modulate HIV infection?

Conservative guess, probably 3-10 million dollars. If Viral could go out and raise $10,000,000 at the current $.05 price they would have to issue another 200,000,000 shares.

Preliminary testing for TPT was positive, and the reason for the partnership with Viral. Shattock currently sits on tens of millions of dollars, so all research on TPT can now be funded.

Viral owns the patents on TPT and would benefit from any positive outcome without the outlay of resources.

This news is the equivalent of Viral putting out a press release that somebody wired them $3-10,000,000 to research TPT without having to issue 1 share of stock…

Don’t take our word, do your own research and Google “Dr Robin Shattock St George’s University London”

http://www.timesonline.co.uk/tol/life_and_style/health/article5786112.ece

http://21webir.com/stocks-and-sectors/disclaimer-for-viral-genetics-vral-pink-sheets/

VRAL potential 10-50 fold winner in the next 18-36 months!!

http://21webir.com/stocks-and-sectors/disclaimer-for-viral-genetics-vral-pink-sheets/

Follow up VRAL Report to be released after the market close:

http://21webir.com/stocks-and-sectors/disclaimer-for-viral-genetics-vral-pink-sheets/

If you haven’t already done so please sign up for our free email alerts:

http://www.21webir.com/subscribe-news-letter.html